H2020Individual fellowship2019–2021

THIAZOLIUMenzyme · Enzyme design and engineering by implementation of non-canonical amino acids in protein scaffolds

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2019-09-15 → 2021-09-14
EU contribution
€191,149
Participants
1
Scheme
MSCA-IF-EF-ST

Lines connect the coordinator with its partners.

Results in brief

Enzyme design and engineering by implementation of non-canonical amino acids in protein scaffolds

There is a growing demand in the chemical and pharmaceutical industry to replace traditional chemical catalysis with environmentally benign approaches for the synthesis of high-value compounds. Enzyme-mediated transformations, i.e. using enzymes as catalysts, generally offer sustainability in combination with high selectivity and catalytic activity. However, most naturally occurring enzymes do not meet the requirements of large-scale industrial processes and/or do not catalyse new-to-nature reactions that are of relevance to the chemical and pharmaceutical industry with sufficient efficiency. As a consequence, the design of enzymes and protein therapeutics with tailored, new-to-nature properties is a long-standing goal in enzymology and cell biology. Nature generally uses 20 amino acids as building blocks for protein synthesis. However, this portfolio limits the options for engineering proteins with ‘un-natural’ activities. Recent developments in the expansion of the genetic code have the potential to revolutionise the design of novel enzymes; by reprogramming the genetic code, we could convey novel functionality into proteins and extend their properties. THIAZOLIUMenzyme aimed at incorporating thiazolium amino acids into the active site of promiscuous and highly evolvable de novo enzymes for orchestrating organocatalytic transformations of clinical and industrial interest. Such reactions, conventionally mediated by non-enzymatic, small molecule N-heterocyclic carbene (NHC) catalysts require high temperature and catalyst loading. It was envisioned that an engineered enzyme with the ability to catalyse such chemistry could overcome the drawbacks of these abiological catalysts, serving as a ‘greener’ biocatalytic alternative, and also perform the desired reactions in cells for medicinal purposes.

Data: CORDIS, © European Union

Project objective

The design of enzymatic catalysts and protein therapeutics with tailored, new-to-nature properties is a long-standing goal in enzymology and cell biology. Nature generally uses 20 amino acids as building blocks for protein synthesis. However, this portfolio limits the options for engineering proteins with ‘un-natural’ activities. Recent developments in the expansion of the genetic code have the potential to revolutionise the design of novel enzymes; by reprogramming the genetic code, we could convey novel functionality into proteins and extend their properties. This project aims at incorporating thiazolium amino acids into the active site of a promiscuous and highly evolvable de novo enzyme, namely the RA95 (retro)-aldolase, for orchestrating organocatalytic transformations of clinical and industrial interest. Such reactions, conventionally mediated by non-enzymatic, small molecule N-heterocyclic carbene (NHC) catalysts require high temperature and catalyst loading. An engineered enzyme with the ability to catalyse such chemistry may overcome the drawbacks of these abiological catalysts, serving as a ‘greener’ biocatalytic alternative, and also perform the desired reactions in cells for medicinal purposes. This initiative will pave the way for development of general strategies for creating enzymes with unique properties and provide a tool-box for efficient, environmentally-friendly and bioorthogonal organocatalysed reactions. It is anticipated that the generated artificial biocatalysts will have attractive applications in research, medicine and industry.

Original text from CORDIS.

Participants

  • EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH · ZuerichCoordinatorSwitzerland

Links

Data: CORDIS, © European Union